BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9467039)

  • 1. Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin.
    Rustum YM; Cao S; Zhang Z
    Cancer J Sci Am; 1998; 4(1):12-8. PubMed ID: 9467039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer.
    Nobile MT; Barzacch MC; Sanguineti O; Chiara S; Gozza A; Vincenti M; Lavarello A; Cognein P; Lionetto R; Percivale PL; Bertoglio S; Murolo C; Esposito M; Vannozzi MO; Rosso R
    Anticancer Res; 1998; 18(1B):517-21. PubMed ID: 9568171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
    Cao S; Troutt AB; Rustum YM
    Cancer Res; 1998 Apr; 58(8):1695-9. PubMed ID: 9563485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
    Grem JL
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-8-S18-18. PubMed ID: 9420016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
    Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
    Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer.
    Tsavaris N; Kosmas C; Gennatas K; Vadiaka M; Paliaros P; Dimitrakopoulos A; Diamantis T; Tsipras H; Papastratis G
    Med Sci Monit; 2002 Sep; 8(9):PI65-9. PubMed ID: 12218954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
    Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomodulation of 5-fluorouracil with antifolates.
    Bertino JR
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
    Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
    Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The biochemical modulation of 5-fluorouracil by leucovorin].
    Borner M; Brunner K
    Schweiz Med Wochenschr; 1991 Aug; 121(33):1149-56. PubMed ID: 1925442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    Saltz LB; Niedzwiecki D; Hollis D; Goldberg RM; Hantel A; Thomas JP; Fields AL; Mayer RJ
    J Clin Oncol; 2007 Aug; 25(23):3456-61. PubMed ID: 17687149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical modulation of combined radiation and 5-fluorouracil treatment of murine tumors by d,l-leucovorin.
    Kovacs CJ; Dainer PM; Evans MJ; Nyce J
    Anticancer Res; 1991; 11(2):905-9. PubMed ID: 2064349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Leucovorin and 5-FU for advanced gastrointestinal cancer].
    Sasaki T; Maeda Y; Kobayashi T
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):440-6. PubMed ID: 10097740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.